Raymond James raises Lexeo Therapeutics price target on trial data
Raymond James raised Lexeo Therapeutics' (LXEO) price target to $42 from $24, citing positive trial data. The stock is down 71% YTD. The firm noted an 80% reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in high-dose patients. Lexeo also completed its acquisition of Mantle Therapeutics for $5.3M in cash and $3M in stock. Other analysts maintain positive ratings with targets ranging from $17 to $35.
How this was made
The 30-second read
Why it matters
The upgraded target reflects belief that the trial data de‑risk the program and could accelerate partnership or licensing opportunities.
Market read
New data and analyst upgrade may drive short‑term price appreciation for LXEO.
What to watch
Regulatory timeline and next‑stage trial funding requirements.
Background
Lexeo Therapeutics is a clinical‑stage biotech developing gene‑therapy for PKP2‑associated cardiomyopathy.
Ticker impact
Raymond James raised its price target to $42 after 12‑month trial data showed 80% reduction in VT episodes, indicating strong clinical progress.
likely upward move as investors price in improved efficacy and higher target
Analyst upgrade based on hard data; market typically reacts positively to late‑stage biotech data.
Market effects
Strengthens outlook for rare‑disease gene‑therapy sector.
US biotech investors may see increased risk‑on sentiment.
Limited to biotech niche, no broad market effect.
Counterpoint
Cash burn remains high; small patient cohort may limit confidence.
Key entities
- analystRaymond James
Raised price target to $42, maintains Strong Buy.
- companyLexeo Therapeutics
Reported 12‑month follow‑up data from HEROICPKP2 trial.

